Raymond James Financial Services Advisors Inc. Sells 5,411 Shares of Hologic, Inc. (NASDAQ:HOLX)

Raymond James Financial Services Advisors Inc. lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 35.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,682 shares of the medical equipment provider’s stock after selling 5,411 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Hologic were worth $692,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Macquarie Group Ltd. raised its holdings in Hologic by 227.2% in the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after acquiring an additional 4,363,687 shares in the last quarter. Norges Bank acquired a new position in Hologic in the fourth quarter valued at about $175,900,000. Arrowstreet Capital Limited Partnership lifted its position in Hologic by 110.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider’s stock worth $145,664,000 after purchasing an additional 995,854 shares during the period. Qube Research & Technologies Ltd grew its stake in Hologic by 117.2% during the third quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock worth $95,651,000 after buying an additional 743,557 shares in the last quarter. Finally, Prudential Financial Inc. increased its holdings in Hologic by 246.0% in the 1st quarter. Prudential Financial Inc. now owns 920,718 shares of the medical equipment provider’s stock valued at $70,730,000 after buying an additional 654,628 shares during the period. Institutional investors own 94.73% of the company’s stock.

Insider Transactions at Hologic

In other news, CFO Karleen Marie Oberton sold 14,940 shares of Hologic stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares in the company, valued at $7,793,700. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Karleen Marie Oberton sold 14,940 shares of Hologic stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at $7,793,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,846 shares of company stock worth $2,473,443. Company insiders own 1.75% of the company’s stock.

Hologic Stock Performance

Shares of Hologic stock opened at $74.92 on Thursday. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The firm has a market capitalization of $17.59 billion, a P/E ratio of 35.51, a P/E/G ratio of 2.62 and a beta of 1.00. The company’s 50 day moving average price is $75.68 and its two-hundred day moving average price is $72.48.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. Hologic’s revenue was down 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.07 earnings per share. On average, equities analysts forecast that Hologic, Inc. will post 4.02 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on HOLX shares. UBS Group increased their price target on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. William Blair restated an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. StockNews.com lowered Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Wednesday, April 10th. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $87.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.